Hurvitz SA, Martin M, Jung KH, et al. Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. ASCO Annual Meeting 2019, abstract 500.
IKNL-visie op efficiënte data-infrastructuur
mei 2019 | Overig